Krankheitskosten neurologischer Erkrankungen in Deutschland

T. Walbert; J.-P. Reese; R. Dodel

doi:10.1055/s-0038-1626857

Nervenheilkunde, Table of Contents

Nervenheilkunde 2007; 26(04): 260-268
DOI: 10.1055/s-0038-1626857

Kompetenznetz: Parkinson

Schattauer GmbH

Krankheitskosten neurologischer Erkrankungen in Deutschland

Cost-of-illness in neurological diseases in Germany

T. Walbert

²University Hospitals Case Medical Center, Cleveland, Ohio, USA

,

J.-P. Reese

¹Klinik für Neurologie, Philipps-Universität Marburg

,

R. Dodel

¹Klinik für Neurologie, Philipps-Universität Marburg

› Author Affiliations

Abstract

Zusammenfassung

Ziel dieser Arbeit ist, eine systematische Übersicht deutscher Krankheitskostenstudien (KKS) neurologischer Erkrankungen vorzulegen. Krankheitskostenstudien dienen als Referenzmaßstäbe für ökonomische Analysen und liefern wichtige Informationen zur Ressourcenallokation für Entscheidungsträger im Gesundheitswesen.

Anhand einer systematischen Literaturrecherche wurden KKS neurologischer Erkrankungen identifiziert und mittels eines strukturierten Fragebogens ausgewertet.

Insgesamt entsprachen 52 Arbeiten den Suchkriterien (Multiple Sklerose 6, Schlaganfall 11, Migräne/Kopfschmerz 6, Epilepsie 4, M. Alzheimer 8, M. Parkinson 15, Dystonie 2). Für Ataxie, Schwindel, ALS und ZNS-Tumoren konnten keine KKS gefunden werden. Die Auswertung der Literatur ergab, dass für viele neurologischen Erkrankungen in Deutschland keine validen Studien zur Verfügung stehen, die das Ausmaß der ökonomischen Belastung für das Gesundheitssystem erkennen lassen würden. Die vorgestellten KKS verdeutlichen die Schwierigkeiten, Kosten, Nutzen und Ressourcenverbrauch neurologischer Erkrankungen transparent darzustellen. Diese Daten sind jedoch wichtig, um eine rationale Diskussion zur Allokation der Ressourcen führen zu können.

Summary

The aim of this work is to present a systematic review of German cost-of-illness (COI) studies of neurological diseases. COI studies serve as references for economic evaluations and provide important information to healthcare decision makers in order to allocate resources.

A systematic literature review was performed to identify COI studies of neurological diseases and information was extracted by using a standardized assessment form. We found 52 studies that matched the search criteria (multiple sclerosis 6, stroke 11, migraine/headache 6, epilepsy 4, Alzheimer’s disease 8, Parkinson’s disease 15, dystonia 2). We were not able to retrieve any COI studies for ataxia, vertigo, ALS or CNS-tumours.

Based on the literature, no valid German studies are available that would allow a detailed assessment of the economic impact of neurological diseases to society.

The reviewed COI studies emphasize the difficulties to present costs, utilities and the use of resources in a transparent way. This information, however, is important to have a rational discussion about the allocation of limited resources in the healthcare systems.

Schlüsselwörter

Kosten - Neurologie - Krankheitskostenstudie - Evidenz - Gesundheitssystem

Keywords

Cost-of-illness - neurology - cost - evidence-based - healthcare system

Full Text

References

Literatur
1 Schöffski O, v. Schulenburg JM. Gesundheitsökonomische Evaluationen. Berlin: Springer; 2000
2 Ekman M, Westphal M. Cost of brain tumour in Europe. Eur J Neurol 2005; 12 (Suppl. 01) 45-49.
3 Hein T, Hopfenmuller W. Projection of the number of multiple sclerosis patients in Germany. Nervenarzt 2000; 71 (04) 288-294.
4 Hauser S. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KB, Wilson J. (ed). Harrison’s principles of internal medicine. New York: McGraw-Hill; 1994: 2281-2294.
5 Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M. Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 2003; 61 (10) 1373-1377.
6 Rieckmann P. Early multiple sclerosis therapy in the effects of public health economics. Med Klinik 2001; 96 (Suppl. 01) 17-21.
7 Kobelt G, Lindgren P, Smala A, Bitsch A, Haupts M, Ko M. et al. Costs and quality of life in multiple sclerosis. An observational study in Germany. Hepac Health Econ Prev Care 2001; 02 (02) 60-68.
8 Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M. et al. Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. JNNP 1998; 65 (04) 460-466.
9 Kobelt G. et al. Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis. Eur J Health Econ 2003; Vol 04 (01) 50-59.
10 Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M. et al. Economic Evaluation of Multiple Sklerosis in the UK, Germany and France. Pharmacoeconomics 1998; 05 (02) 607-622.
11 Heinemann LA, Barth W, Garbe E, Willich SN, Kunze K, Wiesner G. et al. Epidemiologic data of stroke. Data of the WHO-MONICA Project in Germany. Stroke: prevalence, incidence, trends, East-West comparison. Initial results of the 1998 Federal Health Survey. Nervenarzt 1998; 09 (12) 091-1099.
12 Reed SD, Blough DK, Meyer K, Jarvik JG. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. Neurology 2001; 07 (02) 305-314.
13 Evers SM, Ament AJ, Blaauw G. Economic evaluation in stroke research: a systematic review. Stroke 2000; 31 (05) 1046-1053.
14 Grieve R, Hutton J, Bhalla A, Rastenyte D, Ryglewicz D, Sarti C. et al. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Stroke 2001; 32 (07) 1684-1691.
15 Weimar C, Lüngen M, Wagner M, Evers T, Busse O. et al. Kostenanalyse der Schlaganfallbehandlung in Deutschland. Akt Neurol 2002; 29: 181-190.
16 Weimar C, Weber C, Wagner M, Busse O, Haberl RL, Lauterbach KW. et al. Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany. Cerebrovascular Diseases 2003; 15 (1–2): 29-36.
17 Dodel RC, Haacke C, Zamzow K, Pawelzik S, Spottke A, Rethfeldt M. et al. Resource Utilization and Costs of Stroke Unit Care in Germany. Value Health 2004; 07 (02) 144-152.
18 Back T, Schaeg M, Back C, Epifanov Y, Hemmen T, Dodel RC. et al. Costs of stroke unit care in Germany. Resource use and reimbursements by German diagnosis related groups. Nervenarzt 2004; 75 (10) 991-999.
19 Epifanov Y, Dodel R, Haacke C, Schaeg M, Schoffski O, Hennerici M. et al. Costs of acute stroke care on regular neurological wards: A comparison with stroke unit setting. Health Policy. 2007 im Druck.
20 Kolominsky-Rabas PL, Heuschmann PU, Marschall D, Emmert M, Baltzer N, Neundorfer B. et al. Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry: the Erlangen Stroke Project. Stroke 2006; 37 (05) 1179-1183.
21 Neubauer G, Ujlaky R. Migraine -a disease and its costs. Pharm unserer Zeit 2002; 31 (05) 494-497.
22 Larbig W, Bruggenjurgen B. Work productivity and resource consumption among migraineurs under current treatment and during treatment with sumatriptan – An economic evaluation of acute treatment in moderate to severe migraineurs. Headache Quarterly 1997; 08 (03) 237-246.
23 Brüggenjürgen B. Lebensqualität und volkswirtschaftliche Kosten der Migräne in Deutschland. Sankt Augustin: Asgard Verlag Hippe 1994
24 Göbel H, Buschmann P, Heinze A, Heinze-Kuhn K. Epidemiology and socioeconomic consequences of migraine and headache diseases. Versicherungsmedizin 2000; 52 (01) 19-23.
25 Pfäfflin MM, Hermann S, Adelmeier U. Prävalenz, Behandlung und soziale Aspekte von Epilepsien in Deutschland: Erste Ergebnisse einer epidemiologischen Querschnittsstudie (EPIDEGStudie). Epilepsie-Blätter 1997; (10) 15-20.
26 Hamer H, Spottke A, Aletsee C, Knake S, Reis J, Oertel WH. et al. Direct and indirect costs of epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006; 47: 2165-2172.
27 Dodel RC, Pepperl S, Kohne-Volland R, Szucs T, Werhahn KJ, Noachtar S. et al. Costs of drug treatment of neurologic diseases: Parkinson disease, dystonia, epilepsy. Med Klinik 1996; 91 (07) 479-485.
28 Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005; 12 (Suppl. 01) 1-27.
29 van Hout B, Gagnon D, Souetre E, Ried S, Remy C, Baker G. et al. Relationship between seizure frequency and costs and quality of life of outpatients with partial epilepsy in France, Germany, and the United Kingdom. Epilepsia 1997; 38 (11) 1221-1226.
30 Elwood W. Forgotten economic implications of Alzheimer disease. PharmacoEconomics & Outcomes News 1998; 167: 3-4.
31 Bickel H. Dementia in advanced age: estimating incidence and health care costs. Zeitschrift fur Gerontologie und Geriatrie 2001; 34 (02) 108-115.
32 Schulenburg JH, Grobe-Einsler R, Bernhardt T, Möller H, Schulenburg I. Kostenanalyse der Behandlung hirnleistungsgestörter Patienten. Geriatrie Forschung 1995; 05: 31-40.
33 Schulenburg I, Horn R, Möller H, Bernhardt T, Mast O. Cost of Treatment and Care of Alzheimer’s Disease in Germany. In: Wimo AJ, Karlsson G, Winblad B. (ed). Health economics of dementia. Chichester, England: John Wiley& Sons Ltd; 1998: 217-230.
34 Hallauer JFS, Smala A, Berger K. Untersuchung von Krankheitskosten bei Patienten mit Alzheimer-Erkrankung in Deutschland. Gesundheitsökon Qualitätsmanag 2001; 05: 73-79.
35 Kulp W, vd JMSchulenburg. Demographic challenges and medical research. Pharmacoeconomic aspects of treatment of dementia patients. Pharm Zeit 2002; 31 (04) 410-416.
36 Kleinhenz J, Vieregge P, Fassl H, Jörg J. Prävalenz des Morbus Parkinson in der Bundesrepublik Deutschland. Öff Gesundheitswes 1990; 52 (04) 181-190.
37 Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson’s disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10) 1013-1038.
38 Jost WH. Costs in the treatment of parkinsonism. J Neurol 2000; 247 (Suppl. 04) IV31-IV34.
39 Meissner W, Trottenberg T, Klaffke S, Paul G, Kuhn AA, Arnold G. et al. Apomorphine therapy versus deep rain stimulation. Clinical and economic aspects in patients with advanced Parkinson disease. Nervenarzt 2001; 72 (12) 924-927.
40 Muller T, Voss B, Hellwig K, Josef FStein, Schulte T, Przuntek H. Treatment benefit and daily drug costs associated with treating Parkinson’s disease in a Parkinson’s disease clinic. CNS Drugs 2004; 18 (02) 105-111.
41 Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K. et al. Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 2005; 23 (08) 817-836.
42 Stamm TS, Engfer A, Fahrenkrug K. Krankheitskosten des Morbus Parkinson in Deutschland. Psycho 1996; 22: 216-228.
43 Dengler I, Leukel N, Meuser T, Jost WH. Prospective study of the direct and indirect costs of idiopathic Parkinson’s disease. Nervenarzt 2006; 77: 1204-1209.
44 Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH. Analysis of direct costs in therapy of Parkinson disease. Nervenarzt 2003; 74 (12) 1105-1109.
45 Barth F, Baum B, Bremen D, Meuser T, Jost WH. Die indirekten Kosten des idiopathischen Parkinsin-Syndroms. Fortschr Neurol Psychiatr 2005; 73 (04) 187-191.
46 Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH. et al. Inpatient costs, length of stay, and mortality for cerebrovascular events in community hospitals. A comparison of the costs and survival of hospital-admitted stroke patients across Europe. Nervenarzt 2003; 74 (12) 1105-1109.
47 Pollak P, Benabid AL, Limousin P, Benazzouz A, Hoffmann D, Le Bas JF. et al. Subthalamic nucleus stimulation alleviates akinesia and rigidity in parkinsonian patients. Adv Neurol 1996; 69: 591-594.
48 Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease. Neurology 1999; 53 (01) 85-90.
49 Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V. et al. Evaluation of healthcare utilization and health status of patients with Parkinson’s disease treated with deep brain stimulation of the subthalamic nucleus. Journal of Neurology 2002; 249 (06) 759-766.
50 Auger RG, Whisnant JP. Hemifacial spasm in Rochester and Olmsted County, Minnesota, 1960 to 1984. Arch Neurol 1990; 47 (11) 1233-1234.
51 The Epidemiological Study of Dystonia in Europe Collaborative Group – ESDE. A prevalence study of primary dystonia in eight European countries. J Neurol 2000; 247 (10) 787-792.
52 Castelon EKonkiewitz, Trender-Gerhard I, Kamm C, Warner T, Ben-Shlomo Y, Gasser T. et al. Service-based survey of dystonia in Munich. Neuroepidemiology 2002; 21 (04) 202-206.
53 Dodel RC, Kirchner A, Koehne-Volland R, Kunig G, Ceballos-Baumann A, Naumann M. et al. Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics 1997; 12 (06) 695-706.
54 Drummond MF, O’Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd ed.. New York: Oxford University Press; 1997
55 Hannoveraner Konsensusgruppe. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation – Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökonomie und Qualitätsmanagement 1999; (04) A62-A65.